Search results
1 lut 2011 · For empirical coverage of CA-MRSA in outpatients with SSTI, oral antibiotic options include the following: clindamycin (A-II), trimethoprim-sulfamethoxazole (TMP-SMX) (A-II), a tetracycline (doxycycline or minocycline) (A-II), and linezolid (A-II).
15 sie 2011 · Oral antibiotic options for treating skin and soft-tissue infections in patients with community-associated MRSA include clindamycin, trimethoprim/sulfamethoxazole (TMP/SMX; Bactrim,...
14 lis 2022 · Current guidelines governed by the Infectious Diseases Society of America (IDSA) recommend vancomycin (VAN) or daptomycin (DAP) as first-line agents for treating MRSA bacteremia (MRSA). While both have proved to be efficacious, neither is without limitations [ 6 ].
1 lut 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
29 lis 2023 · Methicillin resistance in Staphylococcus aureus (MRSA) is defined by the Clinical Laboratory Standards Institute (CLSI) as an oxacillin minimum inhibitory concentration (MIC) ≥4 mcg/mL [1].
Keywords: Acute bacterial skin and skin structure infection (ABSSSI); Panton-Valentine Leucocidin (PVL); community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA); decolonisation; outpatient parenteral antimicrobial therapy (OPAT); pneumonia; skin and soft tissue infection (SSTI).
3 lut 2021 · These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA.
